Krystal Biotech, Inc. (NASDAQ:KRYS) Stake Trimmed by Bellevue Group AG

Bellevue Group AG lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 36.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,000 shares of the company’s stock after selling 4,500 shares during the quarter. Bellevue Group AG’s holdings in Krystal Biotech were worth $992,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Quest Partners LLC purchased a new position in Krystal Biotech in the 4th quarter worth about $127,000. Pier 88 Investment Partners LLC purchased a new position in Krystal Biotech in the 4th quarter worth about $145,000. Capstone Investment Advisors LLC acquired a new stake in Krystal Biotech during the 4th quarter worth about $303,000. Prime Capital Investment Advisors LLC acquired a new stake in Krystal Biotech during the 4th quarter worth about $310,000. Finally, Graham Capital Management L.P. acquired a new stake in Krystal Biotech during the 3rd quarter worth about $330,000. Hedge funds and other institutional investors own 86.29% of the company’s stock.

Krystal Biotech Price Performance

Shares of Krystal Biotech stock opened at $176.83 on Tuesday. The firm has a market cap of $5.05 billion, a price-to-earnings ratio of 94.56 and a beta of 0.90. Krystal Biotech, Inc. has a 52-week low of $93.95 and a 52-week high of $189.97. The stock has a 50-day simple moving average of $164.79 and a 200-day simple moving average of $143.32.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Monday, May 6th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The company had revenue of $45.25 million during the quarter, compared to analyst estimates of $47.37 million. During the same quarter last year, the firm earned ($1.76) earnings per share. The business’s quarterly revenue was up 452400.0% compared to the same quarter last year. As a group, equities research analysts predict that Krystal Biotech, Inc. will post 2.06 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have commented on KRYS shares. Citigroup raised their price objective on Krystal Biotech from $160.00 to $195.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. HC Wainwright restated a “buy” rating and set a $200.00 price objective on shares of Krystal Biotech in a research report on Monday, May 6th. Guggenheim raised their price objective on Krystal Biotech from $130.00 to $175.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. William Blair restated an “outperform” rating on shares of Krystal Biotech in a research report on Tuesday, February 27th. Finally, Stifel Nicolaus reiterated a “buy” rating and set a $204.00 price target (up from $178.00) on shares of Krystal Biotech in a report on Tuesday, April 16th. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $177.63.

Insider Activity at Krystal Biotech

In related news, Director Julian S. Gangolli sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $164.13, for a total value of $3,282,600.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 14.10% of the stock is owned by company insiders.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).